Drug Profile


Alternative Names: LY-293111; VML 295

Latest Information Update: 22 Jul 2011

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Vernalis
  • Class Anti-inflammatories; Antineoplastics; Benzoic acids
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene B4 receptor antagonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Non-small cell lung cancer; Pancreatic cancer; Psoriasis; Ulcerative colitis

Most Recent Events

  • 22 Jul 2011 Discontinued - Phase-II for Pancreatic cancer in USA (PO)
  • 22 Jul 2011 Discontinued - Phase-II for Non-small cell lung cancer in Europe (PO)
  • 22 Jul 2011 Discontinued - Phase-II for Non-small cell lung cancer in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top